Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity

Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity

Glucocorticoid-induced tumor necrosis factor receptor (GITR) is a co-stimulatory receptor and an important target for cancer immunotherapy. We herein present a potent FcγR-independent GITR agonist IBI37G5 that can effectively activate effector T cells and synergize with anti-programmed death 1 (PD1)...

Full description

Bibliographic Details
Main Authors: Cao, L. (Author), Chen, B. (Author), Chia, T. (Author), Fu, F. (Author), Guan, J. (Author), He, K. (Author), He, L. (Author), Kuang, Z. (Author), Liu, H. (Author), Liu, X. (Author), Lu, J. (Author), Shao, Z. (Author), Sun, G. (Author), Wang, J. (Author), Wang, Z. (Author), Wu, D. (Author), Wu, M. (Author), Wu, W. (Author), Wu, Z. (Author), Xu, W. (Author), Yao, Y. (Author), Zhou, S. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
agonist antibody
cancer immunotherapy
costimulatory receptor
GITR
receptor occupancy
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items